# SPOTLIGHT (NCT03504397)

> A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03504397
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions: zolbetuximab; placebo; oxaliplatin; folinic acid; fluorouracil
- Enrollment: 565
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on SPOTLIGHT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=spotlight-nct03504397